Quick takes on the Social Signals from #ASCO26.
🧬 RASolute-302: @marklewismd 's tweet regarding the standing ovation for RASolute-302 really made that trial stand out. The momentum here was massive, fueled by high expectations from the @RevMedicines PR, #AACR26 presentations,and the high-profile Ben Sasse interviews.
⚔️ PROTEUS: One of the more interesting trials from a social media perspective, as the radiation oncology community on X was highly critical of the trial's surgical paradigm.
🔄 CROWN: Felt a bit like an incredible replay of the Plenary from years ago—steady, practice-confirming data.
🎬 HARMONi-6: Perhaps the most compelling narrative twist. The discussant, Dr. Julie Brahmer, masterfully set up the Plenary audience using The Devil Wears Prada as a research metaphor. It begs the question: Is VEGF back?
🚀 LIBRETTO-432: A massive surprise for many attendees. Lung cancer specialists were thrilled about @LillyOncMed selpercatinib in the adjuvant setting for RET-positive NSCLC. The core takeaway from @christine_lovly presentation was loud and clear: "This is why we test."
🔬 OPTIMA: Really got the breast cancer community excited about using @Veracyte 's test to safely reduce the chemotherapy burden for many of their patients.
📦 WU-KONG28: Had such an interesting vibe. Great data from @Dizal_Global , but it leaves the KOLs asking the same commercial question: Why isn't this readily available to patients in the US yet?
Follow the #ASCO26 Pre and Post highlights here: https://t.co/KmTOtRTvJB
Full room for the proffered papers session on “Advances in Targeting RAS”
Data on OMO-103, ARV-806, ERAS-0015, PT0253, ALTA3263, Daraxonrasib + GnP, and QTX3034!!
#ENASymp26
Promising efficacy signal for RAS(ON) inhibition in 1L pancreatic cancer!
ORR now 61%, median PFS 12.8 months with Daraxonrasib + chemotherapy.
But grade ≥3 TRAEs increased to 73% in the previous update.
Encouraging activity, yet durability, tolerability & randomized validation remain key. #ENA26
@OncoAlert@weoncologists
Durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer: Primary results from the phase IIIb TOURMALINE study
@JHepatology
https://t.co/r6ynz93Cof
👉Shorter durvalumab infusion feasible
👉Efficacy data indicate activity across cohorts
@myESMO@EASLnews@ASCO@ILCAnews
Radiotherapy sentiment in @NYTimes is eye-opening. Since 2009, over half of articles show negative bias towards RT, while only 1/4 are positive. Despite major advancements in tech like MR-Linac, adaptive RT, & heavy ions, media celebration is scarce.
https://t.co/pKK2Bc2u2k
1/7
First impressions and key takeaways from the daraxonrasib plus chemo phase 1 trial in 1L PDAC.
After all those disappointing doublets of the past, are we making progress at last?
https://t.co/UD6cZGZusT
Just 10 drugs accounted for 45% of Medicare Part B drug spending for 340B claims in 2025.
One drug alone accounted for 16%--Keytruda.
---
A new Milliman analysis examined Medicare fee-for-service Part B claims at hospital outpatient departments.
Here were the top five drugs by spending at 340B hospitals in 2025:
💉 Keytruda: $3.2 billion
💉 Darzalex: $1.6 billion
💉 Opdivo: $1.0 billion
💉 Prolia: $0.9 billion
💉 Imfinzi: $0.6 billion
The top 10 drugs accounted for $9.2 billion of the $20.5 billion in Part B drug spending attributed to 340B hospitals.
They represented 14% of drug claims at those hospitals.
---
6/10 drugs were oncology treatments, accounting for $7.1 billion (77%) of the top 10’s spending.
↳ Across all drugs, oncology represented $12 billion (59%) of spending at 340B hospitals.
For most of the top drugs, roughly 70% of Medicare Part B hospital outpatient spending occurred at 340B hospitals.
Note: Milliman identified 340B hospitals using HRSA data and repriced claims to ASP+6%. These figures represent standardized spending attributed to 340B hospitals, not the hospitals’ 340B acquisition costs or the discounts they received.
---
CMS has finalized reducing payment for most separately payable 340B-acquired drugs at affected hospitals from ASP+6% to ASP−28% in 2027.
With spending concentrated among a relatively small number of drugs, the impact on an individual hospital will depend in part on which drugs it administers.
How might hospitals with the greatest exposure to these top drugs respond if the proposal is finalized?
A similar question could be asked about MFP prices for 2029 when Keytruda and Opdivo become eligible for IRA negotiation.
In one of the hardest NCI funding cycles in decades, these institutions captured the most research $
This is the map of where funds flowed in 2026
(full FY'26 dataset in 🧵 below..)
How much of an institution's scientific identity can you infer from the mechanisms that got funded?
▪️MSK & MD Anderson tied at ~$128M each, but their portfolios look remarkably different
▫️Mount Sinai stands out for its unusually large U-series portfolio
▫️ UCSF & Dana-Farber have substantial center/program funding
What are you seeing?
- - - - -
Source: NIH RePORTER via @Jori_health
- - - - -
🎅 Manni is checking his #ASH26 list twice! Naughty or Nice? 🎁 @ajperissinotti@Berninini@ManniMD1
🎙️ On WolverHeme Happy Hour, we dissect the myeloma abstracts and highlight the data that are practice-informing.
https://t.co/oGEi3w8bjR
Video clip of $RVMD CEO at Jeffries, discussing the
👉FAVUS Report of Deaths on RASONQUE in the FAERS (@FDA) database: "It's total nonsense. They took a database that they didn't understand and they came to conclusions that didn't mean anything. so there's nothing..." 2:08
👉Blaming significant Rash on Somebody "typically that means that somebody didn't deal with it early on..." 3:07
👉Regarding Ben Sasse' well-publicized experience on RASONQUE. " I can't really comment on whether that Senator was even taking RASONQUE" 2:58
Love seeing this collab! @OpenEvidence will now pair published evidence with insights from the @OncBrothers podcast experts on how they approach decisions in real-world practice.
Great way to make oncology knowledge more accessible and practical!
Summit Therapeutics was warned twice by the FDA that the Phase 3 trial used to support the application for ivonescimab did not include patients that accurately represented the American population.
https://t.co/o9RmLCFVVH
I'm less concerned these days about confabulated citations.
The more subtle error is when the paper is cited to support a particular argument but doesn't quite support it. Or pulls a number from a table that isn't the one you needed. I think we might see that more as people use AI to summarize papers and then cite them rather than checking the paper.
It takes only minutes to skim a reference that a LLM sources for you and confirm that what it says makes sense. Helps also if you have a general sense of the reliability of the paper. Which in turn requires reading papers...